Systematic identification of small molecule adjuvants

Expert Opinion on Drug Discovery

Volumn 7, Issue 9, 2012, Pages 807-817

  Flower, Darren R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

adjuvants; high throughput screening; vaccines; virtual screening

Indexed keywords

ADJUVANT; BESTATIN; BIS(3',5')CYCLIC DIMERIC GUANOSINE MONOPHOSPHATE; BRYOSTATIN 1; BUPIVACAINE; CL 075; CL 097; GARDIQUIMOD; IMIQUIMOD; IMMUNOSTIMULATING AGENT; ISATORIBINE; LEVAMISOLE; LOXORIBINE; MANNITYL OLEATE; MURAMYL DIPEPTIDE; NATURAL PRODUCT; OLEIC ACID; OLIGONUCLEOTIDE; PHOSPHATE; PHOSPHORYL LIPID A; QS 21; RESIQUIMOD; SM 360320; SMALL MOLECULE ADJUVANT; SQUALENE; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PARTICLE SIZE; VACCINES;

EID: 84865455769     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.699958     Document Type: Review

References (107)

1. Volk VK, Bunney WE. Reimmunization against diphtheria of previously immunized children. Am J Public Health Nations Health 1942;32(7):700-8
2. Volk VK, Bunney WE. Diphtheria immunization with fluid toxoid and alum-precipitated toxoid. Am J Public Health Nations Health 1942;32(7):690-9
3. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007;25(19):3752-62
4. McCluskie MJ, Weeratna RD. Novel adjuvant systems. Curr Drug Targets Infect Disord 2001;1(3):263-71
5. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 2003;17(3):273-81
6. Rey-Ladino J, Ross AG, Cripps AW, et al. Natural products and the search for novel vaccine adjuvants. Vaccine 2011;29(38):6464-71
7. Ragupathi G, Gardner JR, Livingston PO, Gin DY. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 2011;10(4):463-70
8. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998;7(9):1475-82
9. Liu G, Anderson C, Scaltreto H, et al. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine 2002;20(21-22):2808-15
10. Evans TG, McElrath MJ, Matthews T, et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001;19(15-16):2080-91
11. Ogawa C, Liu YJ, Kobayashi KS. Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr Bioactive Compounds 2011;7(3):180-97
12. Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1(1):111-18
13. Enoksson M, Ejendal KF, McAlpine S, et al. Human cord blood-derived mast cells are activated by the Nod1 agonist M-TriDAP to release pro-inflammatory cytokines and chemokines. J Innate Immun 2011;3(2):142-9
14. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316(5831):1628-32
15. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010;667:111-23
16. Schromm AB, Howe J, Ulmer AJ, et al. Physicochemical and biological analysis of synthetic bacterial lipopeptides: validity of the concept of endotoxic conformation. J Biol Chem 2007;282(15):11030-7
17. Coler RN, Baldwin SL, Shaverdian N, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010;5(10):e13677
18. Raman VS, Bhatia A, Picone A, et al. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 2010;185(3):1701-10
19. Buwitt-Beckmann U, Heine H, Wiesmuller KH, et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005;35(1):282-9
20. Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999;19(1):87-93
21. Kalvodova L. Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. Biochem Biophys Res Commun 2010;393(3):350-5
22. Brito LA, Chan M, Baudner B, et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 2011;29(37):6262-8
23. Kensil CR, Wu JY, Anderson CA, et al. QS-21 and QS-7: purified saponin adjuvants. Dev Biol Stand 1998;92:41-7
24. Kensil CR, Wu JY, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 1995;6:525-41
25. Chapman PB, Morrissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin cancer Res 2000;6(3):874-9
26. Moreno CA, Rodriguez R, Oliveira GA, et al. Preclinical evaluation of a synthetic plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice. Vaccine 1999;18(1-2):89-99
27. Hancock GE, Speelman DJ, Frenchick PJ, et al. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 1995;13(4):391-400
28. Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, et al. Acylated and deacylated saponins of quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 2006;24(18):3909-20
29. Soltysik S, Wu JY, Recchia J, et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995;13(15):1403-10
30. Yan H, Chen W. 3',5'-Cyclic diguanylic acid: a small nucleotide that makes big impacts. Chem Soc Rev 2010;39(8):2914-24
31. Chen W, Kuolee R, Yan H. The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine 2010;28(18):3080-5
32. Ebensen T, Libanova R, Schulze K, et al. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/ Th17 promoting mucosal adjuvant. Vaccine 2011;29(32):5210-20
33. Madhun AS, Haaheim LR, Nostbakken JK, et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 2011;29(31):4973-82
34. Yan W, Chen WC, Liu Z, Huang L. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Cytokine 2010;52(3):238-44
35. Clamp A, Jayson GC. The clinical development of the bryostatins. Anticancer Drugs 2002;13(7):673-83
36. Do Y, Hegde VL, Nagarkatti PS, Nagarkatti M. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Cancer Res 2004;64(18):6756-65
37. Li H, Wojciechowski W, Dell'Agnola C, et al. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways. J Immunol 2006;177(6):3554-63
38. Sasaki S, Fukushima J, Hamajima K, et al. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin Exp Immunol 1998;111(1):30-5
39. Peng HJ, Tsai LC, Su SN, et al. Comparison of different adjuvants of protein and DNA vaccination for the prophylaxis of IgE antibody formation. Vaccine 2004;22(5-6):755-61
40. Huang CF, Chu CH, Wu CC, et al. Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Cyn d 1. Int Arch Allergy Immunol 2012;158(2):142-50
41. Lu H, Huo X, Zhang Y, et al. Enhancing effects of the chemical adjuvant levamisole on the DNA vaccine pVIR-P12A-IL18-3C. Microbiol Immunol 2008;52(9):440-6
42. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010;32(1):1-10
43. Smahel M, Polakova I, Sobotkova E, Vajdova E. Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clin Dev Immunol 2011;2011:176759
44. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90(9):4156-60
45. Jin H, Li Y, Ma Z, et al. Effect of chemical adjuvants on DNA vaccination. Vaccine 2004;22(21-22):2925-35
46. McLachlan JB, Shelburne CP, Hart JP, et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 2008;14(5):536-41
47. Stevenson HC, Green I, Hamilton JM, et al. Levamisole - known effects on the immune-system, clinical-results, and future applications to the treatment of cancer. J Clin Oncol 1991;9(11):2052-66
48. Suda H, Aoyagi T, Takeuchi T, Umezawa H. Inhibition of aminopeptidase-B and leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys 1976;177(1):196-200
49. Umezawa H, Aoyagi T, Suda H, et al. Bestatin, an inhibitor of aminopeptidase-B, produced by actinomycetes. J Antibiot 1976;29(1):97-9
50. Brown TCK. History of pediatric regional anesthesia. Pediatr Anesth 2012;22(1):3-9
51. Miller RL, Imbertson LM, Reiter MJ, Gerster JF. Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antivir Res 1999;44(1):31-42
52. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43(1):S6-S11
53. Suzuki H, Wang BH, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114(1):135-41
54. Tomai MA, Miller RL, Lipson KE, et al. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 2007;6(5):835-47
55. Ma F, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 2010;7(5):381-8
56. Dzopalic T, Dragicevic A, Vasilijic S, et al. Loxoribine, a selective toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int Immunopharmacol 2010;10(11):1428-33
57. Sharma BS, Balazs L, Jin A, et al. Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine. Cancer Immunol Immunother 1991;33(2):109-14
58. Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10(4):499-511
59. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009;61(3):248-55
60. Klinman D, Shirota H, Tross D, et al. Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol 2008;84(4):958-64
61. Luganini A, Caposio P, Landolfo S, Gribaudo G. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob Agents Chemother 2008;52(3):1111-20
62. Ballas ZK, Krieg AM, Warren T, et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001;167(9):4878-86
63. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999;67(8):3719-26
64. Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2006;55(10):1267-79
65. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009;27(25-26):3331-4
66. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21(1):23-9
67. Flach TL, Ng G, Hari A, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011;17(4):479-87
68. Seubert A, Calabro S, Santini L, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA 2011;108(27):11169-74
69. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 2010;40(3):638-42
70. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81(1):1-5
71. Gasse P, Riteau N, Charron S, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009;179(10):903-13
72. Denoble AE, Huffman KM, Stabler TV, et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 2011;108(5):2088-93
73. Miyaji EN, Carvalho E, Oliveira ML, et al. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Braz J Med Biol Res 2011;44(6):500-13
74. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv Immunol 2011;109:87-124
75. Zhang X, Kraft A, Broering R, et al. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov 2012;Posted online on May 19, 2012; doi:10.1517/17460441.2012.689281
76. Kersse K, Bertrand MJ, Lamkanfi M, Vandenabeele P. NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor Rev 2011;22(5-6):257-76
77. Ireton RC, Gale M Jr. RIG-I like receptors in antiviral immunity and therapeutic applications. Viruses 2011;3(6):906-19
78. Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 2012;11(2):237-56
79. Jordo ED, Wermeling F, Chen Y, Karlsson MC. Scavenger receptors as regulators of natural antibody responses and B cell activation in autoimmunity. Mol Immunol 2011;48(11):1307-18
80. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev 2009;230(1):38-50
81. Devitt A, Moffatt OD, Raykundalia C, et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392(6675):505-9
82. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 2011;34(5):651-64
83. Gazi U, Martinez-Pomares L. Influence of the mannose receptor in host immune responses. Immunobiology 2009;214(7):554-61
84. Marakalala MJ, Kerrigan AM, Brown GD. Dectin-1: a role in antifungal defense and consequences of genetic polymorphisms in humans. Mamm Genome 2011;22(1-2):55-65
85. Svajger U, Anderluh M, Jeras M, Obermajer N. C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell Signal 2010;22(10):1397-405
86. Bayry J, Flower DR, Tough DF, Kaveri SV. From 'perfect mix' to 'potion magique'-regulatory T cells and anti-inflammatory cytokines as adjuvant targets. Nat Rev Microbiol 2008;6(1):C1; author reply C2
87. Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 2004;18(2):79-93
88. Thanawastien A, Montor WR, Labaer J, et al. Vibrio cholerae proteome-wide screen for immunostimulatory proteins identifies phosphatidylserine decarboxylase as a novel Toll-like receptor 4 agonist. PLoS Pathog 2009;5(8):e1000556
89. Wang J, Zhang W, He A, et al. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia. Oncol Rep 2011;25(2):519-29
90. Buckner D, Wilson S, Kurk S, et al. Use of early passage fetal intestinal epithelial cells in semi-high-throughput screening assays: an approach to identify new innate immune system adjuvants. J Biomol Screen 2006;11(6):664-71
91. Goodchild A, Nopper N, Craddock A, et al. Primary leukocyte screens for innate immune agonists. J Biomol Screen 2009;14(6):723-30
92. Guan Y, Omueti-Ayoade K, Mutha SK, et al. Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening. J Biol Chem 2010;285(31):23755-62
93. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011;57(2):153-60
94. Hattotuwagama CK, Davies MN, Flower DR. Receptor-ligand binding sites and virtual screening. Curr Med Chem 2006;13(11):1283-304
95. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007;11(5):494-502
96. Ripphausen P, Nisius B, Peltason L, Bajorath J. Quo vadis, virtual screening? A comprehensive survey of prospective applications. J Med Chem 2010;53(24):8461-7
97. Bajorath J. Computational studies, virtual screening, and theoretical molecular models. J Med Chem 2010;53(1):1-2
98. Charoenvit Y, Goel N, Whelan M, et al. CEL-1000 - a peptide with adjuvant activity for Th1 immune responses. Vaccine 2004;22(19):2368-73
99. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338(7):436-45
100. Rees S, Morrow D, Kenakin T. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 2002;8(5-6):261-8
101. Gether U, Asmar F, Meinild AK, Rasmussen SG. Structural basis for activation of G-protein-coupled receptors. Pharmacol Toxicol 2002;91(6):304-12
102. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272(5263):872-7
103. Bayry J, Tchilian EZ, Davies MN, et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA 2008;105(29):10221-6
104. Davies MN, Bayry J, Tchilian EZ, et al. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One 2009;4(11):e8084
105. Pere H, Montier Y, Bayry J, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011;118(18):4853-62
106. Sucher AJ, Chahine EB, Nelson M, Sucher BJ. Prevnar 13, the new 13-valent pneumococcal conjugate vaccine. Ann Pharmacother 2011;45(12):1516-24
107. Kresse H, Shah M. Strategic trends in the vaccine market. Nat Rev Drug Discov 2010;9(12):913-14